These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 16224397

  • 1. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ.
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [Abstract] [Full Text] [Related]

  • 2. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

  • 3. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.
    Clin Cancer Res; 2005 Sep 01; 11(17):6212-7. PubMed ID: 16144923
    [Abstract] [Full Text] [Related]

  • 4. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 5. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ.
    Cancer Res; 2001 Dec 15; 61(24):8654-8. PubMed ID: 11751380
    [Abstract] [Full Text] [Related]

  • 6. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 15; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 7. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 15; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 8. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 9. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, Ma Y, Wuren T, Ge RL.
    J Cancer Res Ther; 2013 Nov 20; 9(3):410-5. PubMed ID: 24125975
    [Abstract] [Full Text] [Related]

  • 10. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M.
    Int J Oncol; 2008 May 20; 32(5):1091-6. PubMed ID: 18425336
    [Abstract] [Full Text] [Related]

  • 11. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 20; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 12. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.
    Clin Lung Cancer; 2009 Mar 20; 10(2):118-23. PubMed ID: 19362955
    [Abstract] [Full Text] [Related]

  • 13. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.
    J Clin Oncol; 2007 Apr 01; 25(10):1247-54. PubMed ID: 17401013
    [Abstract] [Full Text] [Related]

  • 14. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb 01; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 16. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 17. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep 10; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 18. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.
    Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ, Su L, Christiani DC.
    Cancer Epidemiol Biomarkers Prev; 2005 Feb 10; 14(2):491-6. PubMed ID: 15734977
    [Abstract] [Full Text] [Related]

  • 19. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M.
    Oncology; 2007 Feb 10; 72(5-6):364-70. PubMed ID: 18204222
    [Abstract] [Full Text] [Related]

  • 20. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug 10; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.